Bioretec (BRETEC) Investor presentation summary

Company overview and history

• Develops, manufactures, and sells absorbable orthopedic implants with global operations and headquarters in Finland.

• Publicly listed on Nasdaq First North Growth Market Finland, with subsidiaries in Austria and the U.S.

• Eight registered product families, with products available in about 40 countries.

• 2023 revenue reached €4 million.

• Key milestones include FDA breakthrough designation and launch of RemeOs™ trauma screw in the US.

Product portfolio and innovation

• Offers Activa product lines based on biopolymer (SR-PLGA) and next-generation RemeOs™ lines based on absorbable metal (Mg-Zn-Ca).

• RemeOs™ products target expanded indications and are now commercially available.

• Product range includes pins, nails, screws, plates, staples, and spinal cages for various anatomical locations.

• RemeOs™ Spinal Interbody Cage is a strategic focus, with development milestones including FDA breakthrough designation and patenting.

Clinical challenges and RemeOs™ solutions

• Current spinal cages face issues like non-union, subsidence, adjacent segment disease, bone resorption, and MRI artifacts.

• RemeOs™ Spinal Cage uses an absorbable alloy to promote bone growth, match bone strength, and avoid permanent foreign materials.

• Hybrid composite design with antimicrobial bioglass shell slows degradation and reduces infection risk.

• Radiolucency enables artifact-free imaging, and the device gradually degrades, leaving only new bone.